Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

Biochemical Pharmacology

Volumn 79, Issue 5, 2010, Pages 688-697

  Donato, Nicholas J ^a   Fang, Dexing ^a   Sun, Hanshi ^a   Giannola, Diane ^a   Peterson, Luke F ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Inhibitor; Kinase; Leukemia; Resistance; Signal transduction

Indexed keywords

AURORA KINASE; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; IMATINIB; PROTEIN KINASE LYN; PROTEIN MDM2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 71849102704     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.009     Document Type: Article

References (39)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 December 15(13) (2008) 4808-4817
2. Quintás-Cardama A., and Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113 February 19(8) (2009) 1619-1630 Epub 2008 Sep 30
3. Hochhaus A. First-line management of CML: a state of the art review. J Natl Compr Canc Netw 6 March (Suppl. 2) (2008) S1-S10
4. O'Hare T., Eide C.A., and Deininger M.W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 17 June (6) (2008) 865-878
5. Quintás-Cardama A., Kantarjian H., and Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6 October (10) (2007) 834-848
6. Quintás-Cardama A., and Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14 July 15 (14) (2008) 4392-4399
7. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117 9 (2007) 2562-2569 Sep
8. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 July 16 (5682) (2004) 399-401
9. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., Biggs III W.H., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res 66 January 15 (2) (2006) 1007-10014
10. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 January 15 (2) (2007) 500-502
11. Cheetham G.M., Charlton P.A., Golec J.M., and Pollard J.R. Structural basis for potent inhibition of the aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 251 June 28 (2) (2007) 323-329
12. Akahane D., Tauchi T., Okabe S., Nunoda K., and Ohyashiki K. Activity of a novel aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci 99 June (6) (2008) 1251-1257
13. Okabe S., Tauchi T., Ohyashiki J.H., and Ohyashiki K. Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochem Biophys Res Commun 380 March 20 (4) (2009) 775-779
14. Dai Y., Chen S., Venditti C.A., Pei X.Y., Nguyen T.K., Dent P., et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 112 August 1 (3) (2008) 793-804
15. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., et al. Inhibition of drug-resistant mutants of ABL: KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102 August 2 (31) (2005) 11011-11016
16. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 10 March (3) (2004) 262-267
17. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 January 15 (2) (2003) 690-698
18. Bartholomeusz G.A., Talpaz M., Kapuria V., Kong L.Y., Wang S., Estrov Z., et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109 April 15 (8) (2007) 3470-3478
19. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64 January 15 (2) (2004) 672-677
20. Estrov Z., Talpaz M., Zipf T.F., Kantarjian H.M., Ku S., Ouspenskaia M.V., et al. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol 166 March (3) (1996) 618-630
21. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100 July 2 (13) (2008) 926-939
22. He Z., Cho Y.Y., Ma W.Y., Choi H.S., Bode A.M., and Dong Z. Regulation of ultraviolet B-induced phosphorylation of histone H3 at serine 10 by Fyn kinase. J Biol Chem 280 January 28 (4) (2005) 2446-2454
23. Kojima K., Konopleva M., Tsao T., Nakakuma H., and Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112 October 1 (7) (2008) 2886-2895
24. Gizatullin F., Yao Y., Kung V., Harding M.W., Loda M., and Shapiro G.I. The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66 August 1 (15) (2006) 7668-7677
25. Dreier M.R., Grabovich A.Z., Katusin J.D., and Taylor W.R. Short and long-term tumor cell responses to aurora kinase inhibitors. Exp Cell Res 315 April 15 (7) (2009) 1085-1099
26. Shangary S., and Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49 (2009) 223-241
27. Christopher L.J., Cui D., Wu C., Luo R., Manning J.A., Bonacorsi S.J., et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36 July (7) (2008) 1357-1364
28. Fabarius A., Giehl M., Rebacz B., Krämer A., Frank O., Haferlach C., et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93 August (8) (2008) 1145-1154
29. Ilaria Jr. R.L. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematol Am Soc Hematol Educ Program (2005) 188-194
30. Buser C.A., Haregewoin A., Furey B., Harding M.W., Hoover R., and Pollard J. Contributions of MK-0457 kinase inhibitory activity to clinical activity. 12th Congress of the European Hematology Association (2007) [abstract #913]
31. Dar A.A., Belkhiri A., Ecsedy J., Zaika A., and El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68 November 1 (21) (2008) 8998-9004
32. Zhang D., Shimizu T., Araki N., Hirota T., Yoshie M., Ogawa K., et al. Aurora-A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene 27 July 17 (31) (2008) 4305-4314
33. Liu Q., Kaneko S., Yang L., Feldman R.I., Nicosia S.V., Chen J., et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279 December 10 (50) (2004) 52175-52182
34. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36 January (1) (2004) 55-62
35. Neubauer A., He M., Schmidt C.A., Huhn D., and Liu E.T. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 7 April (4) (1993) 593-600
36. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 June 1 (11) (2004) 4010-4022
37. Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68 December 1 (23) (2008) 9809-9816
38. Wissing J., Godl K., Brehmer D., Blencke S., Weber M., Habenberger P., et al. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics 3 December (12) (2004) 1181-1193
39. Dorsey J.F., Jove R., Kraker A.J., and Wu J. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60 June 15 (12) (2000) 3127-3131